Inhibrx Biosciences Inc（INBX）財務資料INBXInhibrx Biosciences Inc

Evaluating the bottom line, Inhibrx Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -1773.60%, provide a clear picture of how effectively INBX converts its operational activities into shareholder value.

In the context of the broader market, INBX competes directly with industry leaders such as KMDA and TYRA. With a market capitalization of $1.37B, it holds a significant position in the sector. When comparing efficiency, INBX's gross margin of N/A stands against KMDA's 40.91% and TYRA's N/A. Such benchmarking helps identify whether Inhibrx Biosciences Inc is trading at a premium or discount relative to its financial performance.

Inhibrx has a gross margin of 100% for the last reported quarter, indicating strong potential for profitability if revenues increase. However, the company has reported consistent net losses, with a net income of -33.64 million for Q2 2026.